<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Staging work-up and surveillance of cutaneous melanoma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Staging work-up and surveillance of cutaneous melanoma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Staging work-up and surveillance of cutaneous melanoma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Antonio C Buzaid, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey E Gershenwald, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael B Atkins, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hensin Tsao, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 03, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous melanoma has the potential to metastasize to any organ, including the skin, lymph nodes, subcutaneous tissues, lungs, liver, bone, brain, and visceral organs. Various laboratory tests, histologic evaluations, and imaging studies are necessary to accurately stage patients with cutaneous melanoma prior to definitive treatment and for surveillance (during therapy and after treatment completion).
        </p>
        <p>
         Because there have been important advances in the treatment of patients with melanoma and many can be cured of their disease, it is important to accurately identify even low-volume systemic disease at initial evaluation and during surveillance. However, there are limited high-quality data that define the appropriate tests for initial evaluation and subsequent follow-up in such patients [
         <a href="#rid1">
          1
         </a>
         ]. Additionally, the options for and availability of these imaging studies may also vary by institutional practice and geographic location. As such, we acknowledge that there may be variations in clinical practice and guidelines.
        </p>
        <p>
         For patients with a confirmed pathological diagnosis of primary cutaneous melanoma, our approach to initial staging work-up and surveillance is presented here. The clinical features and diagnosis of melanoma; the tumor, node, metastasis (TNM) melanoma staging system; imaging studies used in melanoma; and clinical features, diagnosis, and management of noncutaneous (ie, mucosal, uveal, conjunctival) melanoma are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15806.html" rel="external">
          "Melanoma: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7618.html" rel="external">
          "Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7625.html" rel="external">
          "Imaging studies in melanoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16904.html" rel="external">
          "Locoregional mucosal melanoma: Epidemiology, clinical diagnosis, and treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7617.html" rel="external">
          "Initial management of uveal and conjunctival melanomas"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H389939922">
         <span class="h1">
          IMAGING MODALITIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Available imaging modalities for patients with melanoma who are undergoing staging work-up or surveillance include (see
         <a class="medical medical_review" href="/z/d/html/7625.html" rel="external">
          "Imaging studies in melanoma"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Computed tomography (CT) of the chest, abdomen, pelvis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CT of the neck is indicated for patients with primary tumors or lymph node involvement in the head and neck region
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Whole-body fluorodeoxyglucose (FDG) positron emission tomography (PET)-CT (ie, scalp to toes and all extremities)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Magnetic resonance imaging (MRI) of the brain
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nodal basin ultrasound (US) for assessment of regional lymph nodes (see
         <a class="local">
          'Indications for nodal ultrasound during surveillance'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/7616.html" rel="external">
          "Evaluation and management of regional nodes in primary cutaneous melanoma"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest radiographs are less commonly and nonuniformly used across institutions [
         <a href="#rid2">
          2
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Bone scans are not routinely used due to limited specificity and relatively low incidence of isolated melanoma bone metastases. (See
         <a class="medical medical_review" href="/z/d/html/7625.html" rel="external">
          "Imaging studies in melanoma", section on 'Bone metastases'
         </a>
         .)
        </p>
        <p>
         CT and MRI should be performed with appropriate intravenous contrast (and oral contrast for CT imaging) unless the patient has a clinical contraindication to such contrast. (See
         <a class="medical medical_review" href="/z/d/html/113083.html" rel="external">
          "Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">
          "Patient evaluation before gadolinium contrast administration for magnetic resonance imaging"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3927902332">
         <span class="h1">
          STAGING WORK-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with a new diagnosis of primary cutaneous melanoma, the purpose of initial staging work-up is to assess for disease involvement of the locoregional lymph node and distant metastases. Such information will contribute to the final disease staging (based on the American Joint Committee on Cancer [AJCC] eighth edition staging system for melanoma  (
         <a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/z/d/graphic/110663.html" rel="external">
          table 1A-B
         </a>
         )) and guide treatment options.
        </p>
        <p>
         Prior to initial staging work-up, patients should have a confirmed pathological diagnosis of the primary melanoma (via biopsy or surgical excision). Depending upon Breslow depth and ulceration, some patients may undergo wide local excision and sentinel lymph node biopsy (SLNB) prior to staging work-up. These interventions are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/15806.html" rel="external">
          "Melanoma: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7620.html" rel="external">
          "Surgical management of primary cutaneous melanoma or melanoma at other unusual sites"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7616.html" rel="external">
          "Evaluation and management of regional nodes in primary cutaneous melanoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1033004987">
         <span class="h2">
          Clinically negative nodes at presentation
         </span>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h3">
          Melanoma in situ and clinical or pathological stage IA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with melanoma in situ and clinical or pathological stage I melanoma present with no clinical evidence of lymph node involvement on physical exam  (
         <a class="graphic graphic_table graphicRef110663" href="/z/d/graphic/110663.html" rel="external">
          table 1A
         </a>
         and
         <a class="graphic graphic_table graphicRef110664" href="/z/d/graphic/110664.html" rel="external">
          table 1B
         </a>
         ). For those who are asymptomatic, there is no established role for routine laboratory or imaging studies. Imaging studies have limited ability to identify metastatic disease in these patients with excellent ten-year melanoma-specific survival (MSS) rates of 98 percent or greater  (
         <a class="graphic graphic_figure graphicRef134100" href="/z/d/graphic/134100.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid3">
          3,4
         </a>
         ]. Chest radiographs [
         <a href="#rid5">
          5-10
         </a>
         ]; CT of the brain, neck, chest, abdomen, and pelvis [
         <a href="#rid6">
          6,7,9-11
         </a>
         ]; and positron emission tomography (PET)-CT [
         <a href="#rid12">
          12-17
         </a>
         ] have low detection rates for occult regional lymph node involvement and distant metastases and can result in false-positive imaging findings.
        </p>
        <p>
         For patients with invasive melanoma who are symptomatic, systemic imaging may be obtained to evaluate specific signs and symptoms, as indicated. (See
         <a class="local">
          'Symptomatic disease or suspected metastases'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2123795204">
         <span class="h3">
          Clinical stage IIC (pT4b cN0)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with a pT4b primary tumor (ie, primary tumor thickness &gt;4 mm with ulceration) and clinically negative nodes have clinical stage IIC disease  (
         <a class="graphic graphic_table graphicRef110664 graphicRef110663" href="/z/d/graphic/110664.html" rel="external">
          table 1A-B
         </a>
         ). If possible, we typically obtain systemic imaging with a CT of the chest, abdomen, and pelvis to assess for metastatic disease prior to wide excision and SLNB, since these patients are at higher risk for metastatic disease than other patients who present with primary cutaneous melanoma. We also obtain a CT of the neck for those with a primary melanoma in the head and neck region. Patients with imaging studies that demonstrate no evidence of metastatic disease may proceed with planned initial definitive surgical treatment, which usually includes wide excision of the primary tumor and regional nodal evaluation with lymphatic mapping and sentinel node biopsy. (See
         <a class="local">
          'Pathological stage IIC and IIIB'
         </a>
         below.)
        </p>
        <p>
         It is important to consider systemic imaging in patients with clinical stage IIC disease because the presence of ulceration and tumor thickness &gt;4 mm of the primary tumor are high-risk prognostic features [
         <a href="#rid1">
          1,18
         </a>
         ]. Patients with pathological stage IIC disease also have lower five- and ten-year MSS rates (82 and 75 percent, respectively  (
         <a class="graphic graphic_figure graphicRef134100" href="/z/d/graphic/134100.html" rel="external">
          figure 1
         </a>
         )) than those with stage IIIA disease (93 and 88 percent, respectively  (
         <a class="graphic graphic_figure graphicRef116999" href="/z/d/graphic/116999.html" rel="external">
          figure 2
         </a>
         )) [
         <a href="#rid3">
          3
         </a>
         ] who are typically imaged for metastatic disease at diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/7618.html" rel="external">
          "Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3279197791">
         <span class="h2">
          Clinically suspicious or equivocal clinical nodes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with a primary melanoma of any tumor thickness and clinically suspicious or equivocal lymph nodes on physical exam are candidates for nodal basin ultrasound (US) prior to lymph node biopsy [
         <a href="#rid19">
          19
         </a>
         ]. Lymph nodes suspicious for disease on nodal basin US are typically sampled using image-guided (eg, US or CT) fine needle aspiration or core biopsy; excisional lymph node biopsy is generally not recommended. Patients with a normal nodal basin US should undergo SLNB, if clinically indicated at the time of primary tumor wide excision, based on clinical factors and pathological features of the primary tumor. (See
         <a class="medical medical_review" href="/z/d/html/7616.html" rel="external">
          "Evaluation and management of regional nodes in primary cutaneous melanoma"
         </a>
         .)
        </p>
        <p>
         Any confirmed disease involvement in the lymph nodes would subsequently modify tumor stage to stage III disease and influence further imaging work-up. (See
         <a class="local">
          'Following pathological lymph node assessment'
         </a>
         below.)
        </p>
        <p>
         Further details on the initial evaluation and treatment of regional lymph nodes in melanoma are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7616.html" rel="external">
          "Evaluation and management of regional nodes in primary cutaneous melanoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2020811587">
         <span class="h2">
          Clinically evident lymph nodes or in-transit/satellite metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who present with clinically detected locoregional melanoma, such as clinically evident nodal disease or in-transit/satellite metastases  (
         <a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/z/d/graphic/110663.html" rel="external">
          table 1A-B
         </a>
         ), we obtain systemic imaging with whole-body PET-CT prior to further regional nodal evaluation, if possible. In particular, those with an extremity primary may present with soft tissue metastases on the extremities that may be missed on CT imaging alone or physical exam. CT of the neck, chest, abdomen, and pelvis is also an option for those with primary tumors of the head, neck, and trunk who are less likely to present with metastatic disease in the extremities. We also obtain central nervous system (CNS) imaging with magnetic resonance imaging (MRI) of the brain to assess for intracranial metastases as part of staging work-up. Other indications for CNS imaging include the presence of neurologic symptoms, documented extracranial metastatic disease on initial CT imaging, or evaluation for clinical trials.
        </p>
        <p>
         Data from observational studies [
         <a href="#rid1">
          1,20-22
         </a>
         ] and several meta-analyses [
         <a href="#rid23">
          23,24
         </a>
         ] support the accuracy of PET-CT in detecting metastases during the staging of patients with more extensive nodal disease. As an example, one systematic review and meta-analysis of nine studies investigating the value of PET-CT in 623 patients with stage III melanoma included a subset of 418 patients (67 percent) with clinically palpable nodes and/or in-transit disease. In this study, for all patients, the sensitivity and specificity of a staging PET-CT for detecting distant metastases were 89 percent each, respectively [
         <a href="#rid24">
          24
         </a>
         ]. Additionally, a change in management based on PET-CT results was noted in 22 percent of all patients and 26 percent of those with clinically palpable nodes and/or in-transit disease. However, the interpretation of PET-CT can still be complicated by false negatives, false positives, and the identification of second primaries [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7625.html" rel="external">
          "Imaging studies in melanoma", section on 'FDG PET and PET/CT'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3363302997">
         <span class="h2">
          Following pathological lymph node assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with a completed SLNB or other pathological lymph node evaluation that is either positive or negative for disease will have a confirmed pathological nodal (N) category  (
         <a class="graphic graphic_table graphicRef110664 graphicRef110663" href="/z/d/graphic/110664.html" rel="external">
          table 1A-B
         </a>
         ). SLNB identifies patients with clinically occult, pathologically positive sentinel lymph nodes who are at increased risk for developing metastatic disease [
         <a href="#rid25">
          25
         </a>
         ]. Therefore, we assess for distant metastases (M category) using a common approach for specific groups that have similar prognoses and true-positive detection rates for metastatic disease  (
         <a class="graphic graphic_figure graphicRef134094" href="/z/d/graphic/134094.html" rel="external">
          figure 3
         </a>
         ). In general, as prognostic stage group increases, the chances of detecting a true positive increases and false positive decreases. However, we recognize that there is significant variability in clinical practice and alternatives exist to the staging work-up suggested below.
        </p>
        <p class="headingAnchor" id="H843592222">
         <span class="h3">
          Pathological stage IB and IIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with pathological stage IB and stage IIA melanoma who are asymptomatic, most UpToDate contributors do not obtain routine imaging studies, as the chances of detecting true metastatic disease is extremely low. Alternatively, one UpToDate contributor offers a chest radiograph and abdominal US for baseline imaging.
        </p>
        <p>
         For symptomatic patients, systemic imaging may be obtained to evaluate specific signs and symptoms, as indicated. (See
         <a class="local">
          'Symptomatic disease or suspected metastases'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1305122523">
         <span class="h3">
          Pathological stage IIB and IIIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with pathological stage IIB or IIIA melanoma  (
         <a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/z/d/graphic/110663.html" rel="external">
          table 1A-B
         </a>
         ), we obtain a CT of the chest, abdomen, and pelvis. We also obtain a CT of the neck for those with primary tumors or lymph node involvement in the head and neck region. These CT scans may also serve as baseline imaging for patients with indications for adjuvant therapy. (See
         <a class="medical medical_review" href="/z/d/html/7615.html" rel="external">
          "Adjuvant and neoadjuvant therapy for cutaneous melanoma", section on 'Factors that influence therapy'
         </a>
         .)
        </p>
        <p>
         We offer the same initial staging work-up for stage IIB and IIIA disease, which have similar prognoses and risk for metastatic disease [
         <a href="#rid3">
          3
         </a>
         ]. While CT imaging is frequently obtained to stage patients with stage III disease, data are limited in those with stage IIB disease [
         <a href="#rid26">
          26
         </a>
         ]. CT imaging has a low yield for detecting distant metastases, but it can often identify false-positive abnormalities at staging and thereby function as a baseline for future surveillance imaging.
        </p>
        <p>
         We do not generally obtain a whole-body PET-CT or CNS imaging with MRI of the brain [
         <a href="#rid27">
          27-29
         </a>
         ]. However, some patients may still receive such imaging in select situations, such as potential disease-related symptoms, further evaluation of equivocal findings for metastatic disease on initial CT imaging, or enrollment in clinical trials. For these imaging studies, observational data suggest low detection rates (less than 5 percent true-positive rate) [
         <a href="#rid27">
          27-31
         </a>
         ] and high false-positive rates (approximately 10 percent or more) for metastatic disease in both stage IIB [
         <a href="#rid32">
          32-34
         </a>
         ] and IIIA disease [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="local">
          'Symptomatic disease or suspected metastases'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/7615.html" rel="external">
          "Adjuvant and neoadjuvant therapy for cutaneous melanoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H775063230">
         <span class="h3">
          Pathological stage IIC and IIIB
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with pathological stage IIC and IIIB melanoma, we obtain a CT of the chest, abdomen, and pelvis. We also obtain a CT of the neck for those with primary tumor or lymph nodes involving the head and neck region. Some UpToDate contributors offer the option of a whole-body PET-CT at diagnosis as a baseline imaging study to compare with future imaging studies. We do not generally obtain CNS imaging unless patients have suspected neurologic symptoms related to disease, documented extracranial metastatic disease on initial imaging, or are being evaluated for clinical trials [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2635895582">
         <span class="h3">
          Pathological stage IIIC and IIID
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with pathological stage IIIC and IIID melanoma, options for initial staging include CT of the chest, abdomen, and pelvis (and neck for those with primary tumor or lymph nodes involving the head and neck region) or whole-body PET-CT. The choice between these imaging studies is based on clinician preference and the chosen adjuvant therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some UpToDate contributors obtain whole-body PET-CT imaging in these high-risk patients to enhance the detection of distant metastatic disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other contributors prefer CT imaging over PET-CT because it images lesions more accurately at baseline and can also be used as comparison for future surveillance imaging studies obtained during adjuvant therapy. Additionally, for patients actively receiving adjuvant therapy with checkpoint inhibitor immunotherapy, an active immune response could falsely increase the standardized uptake value on PET-CT in tumor tissue and create a false impression of disease progression [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15863.html" rel="external">
          "Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Imaging studies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We obtain CNS imaging with MRI of the brain in all patients with pathological stage IIIC or IIID melanoma. (See
         <a class="medical medical_review" href="/z/d/html/7625.html" rel="external">
          "Imaging studies in melanoma"
         </a>
         and
         <a class="local">
          'Symptomatic disease or suspected metastases'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2817953">
         <span class="h2">
          Symptomatic disease or suspected metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with symptomatic disease or clinically suspected systemic metastases (eg, based on physical exam, laboratory evaluation, or imaging studies obtained for other indications) should receive the following staging work-up prior to regional nodal evaluation, if possible. (See
         <a class="local">
          'Symptoms of recurrence or metastatic disease'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Options for cross-sectional imaging include CT of the chest, abdomen, and pelvis (and neck for those with primary tumors or lymph nodes involving the head and neck region) or whole-body PET-CT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A serum lactate dehydrogenase (LDH) can be obtained. LDH is incorporated into the TNM staging system (for stage IV, distant metastasis [M-category], only) and is a marker of more aggressive disease in patients with distant metastasis. (See
         <a class="medical medical_review" href="/z/d/html/7618.html" rel="external">
          "Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MRI of the brain should also be obtained in all patients with neurologic symptoms and/or suspected metastatic disease.
        </p>
        <p>
        </p>
        <p>
         CT is an adequate and reliable baseline for measuring future response to therapy, in particular immunotherapy. This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/15863.html" rel="external">
          "Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Imaging studies'
         </a>
         .)
        </p>
        <p>
         PET-CT can be used to rule out systemic metastases in patients eligible for potentially curable resection or to evaluate an area suspicious for metastatic disease that is being targeted for biopsy [
         <a href="#rid22">
          22,37-39
         </a>
         ]. In one retrospective study with 250 patients with cutaneous melanoma, PET-CT detected significantly more visceral and nonvisceral metastases (98.7 percent) versus CT (69.7 percent) [
         <a href="#rid40">
          40
         </a>
         ]. Similarly, in a systematic review, PET-CT had higher sensitivity for detecting metastases in stage IIIC or IV disease versus less-advanced disease (100 versus 84 percent, respectively) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Other imaging studies may also be ordered on the basis of symptoms and disease site. (See
         <a class="medical medical_review" href="/z/d/html/7625.html" rel="external">
          "Imaging studies in melanoma", section on 'Approach to patient imaging based on disease site'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2818027">
         <span class="h1">
          SURVEILLANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with cutaneous melanoma, the primary objective of surveillance during and after treatment is to identify locoregional recurrences that are potentially curable, second primary melanomas, and low-volume distant metastatic disease that can be effectively treated with systemic therapy. (See
         <a class="medical medical_review" href="/z/d/html/15863.html" rel="external">
          "Systemic treatment of metastatic melanoma lacking a BRAF mutation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">
          "Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"
         </a>
         .)
        </p>
        <p>
         Prior to the era of contemporary therapies for melanoma, the major value of surveillance visits was to detect locoregional recurrences that could potentially be cured with resection. With the advent of effective systemic therapies, such as immunotherapy and targeted therapy, the paradigm for surveillance continues to evolve [
         <a href="#rid1">
          1
         </a>
         ]. Since there is no consensus as to the optimal strategy for surveillance, we acknowledge that there are significant variations in clinical practice [
         <a href="#rid19">
          19,41,42
         </a>
         ] based on institutional practices, geographic location, available imaging resources [
         <a href="#rid43">
          43,44
         </a>
         ], goals of care, and patient preferences.
        </p>
        <p>
         Important clinical factors that influence our approach to the surveillance of treated melanoma include stage of disease, risk of recurrence, choice of therapy (eg, locoregional versus systemic treatment), and treatment response. For older adults or those with extensive comorbidities, clinicians may also take into account a patient's preferences on extent and duration of surveillance. We do not routinely use gene expression profiling to determine surveillance of cutaneous melanoma, which is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7618.html" rel="external">
          "Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma", section on 'Gene expression profiling and proteomics'
         </a>
         .)
        </p>
        <p>
         These surveillance guidelines are intended for patients without signs or symptoms of recurrence, progression, or new primary melanoma; such patients should undergo appropriate restaging work-up as clinically indicated. (See
         <a class="local">
          'Staging work-up'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3651461404">
         <span class="h2">
          Symptoms of recurrence or metastatic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients who are undergoing surveillance for melanoma should be educated on symptoms that could potentially indicate recurrence of melanoma or metastatic disease and warrant further work-up [
         <a href="#rid45">
          45
         </a>
         ], such as:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fatigue
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight loss
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cutaneous, intradermal, or subcutaneous nodules
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Swollen or painful lymph nodes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Shortness of breath or cough
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abdominal swelling or pain
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone pain or fractures
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Central nervous system (CNS) symptoms (eg, headaches, seizures, weakness, or numbness)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1489591693">
         <span class="h2">
          Pathological stage IA
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with pathological stage I disease  (
         <a class="graphic graphic_table graphicRef110663" href="/z/d/graphic/110663.html" rel="external">
          table 1A
         </a>
         and
         <a class="graphic graphic_table graphicRef110664" href="/z/d/graphic/110664.html" rel="external">
          table 1B
         </a>
         ) who are asymptomatic, we offer routine physical exam, including total-body skin examination (see
         <a class="medical medical_review" href="/z/d/html/4845.html" rel="external">
          "Screening for melanoma in adults and adolescents", section on 'Performing skin examination'
         </a>
         ) and clinical evaluation of regional lymph nodes, every six months for the first two years, then annually [
         <a href="#rid19">
          19,46
         </a>
         ]; however, patients with Familial Atypical Mole and Melanoma (FAMM) syndrome or a family history suggestive of hereditary melanoma should continue to be clinically evaluated every six months. No other routine laboratory tests or imaging tests are indicated [
         <a href="#rid11">
          11
         </a>
         ]. Patients may be referred to the primary care physician, dermatologist, and/or a survivorship clinic after two years and should be educated on the potential symptoms of recurrence or metastases. (See
         <a class="local">
          'Symptoms of recurrence or metastatic disease'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7624.html" rel="external">
          "Inherited susceptibility to melanoma"
         </a>
         .)
        </p>
        <p>
         Patients should undergo continued dermatologic surveillance including total-body skin examination (see
         <a class="medical medical_review" href="/z/d/html/4845.html" rel="external">
          "Screening for melanoma in adults and adolescents", section on 'Performing skin examination'
         </a>
         ) because of the risk of a second primary, particularly if atypical nevi are present. The incidence of a second melanoma is increased in melanoma survivors, with the cumulative risk ranging from 2 to 5 percent at periods 5 to 20 years after initial diagnosis [
         <a href="#rid41">
          41,47,48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4844.html" rel="external">
          "Melanoma: Epidemiology and risk factors", section on 'Personal history of melanoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4845.html" rel="external">
          "Screening for melanoma in adults and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H879901470">
         <span class="h2">
          Pathological stage IB and IIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with pathological stage IB and IIA disease who are asymptomatic  (
         <a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/z/d/graphic/110663.html" rel="external">
          table 1A-B
         </a>
         ), we offer a physical exam, including a total-body skin examination (see
         <a class="medical medical_review" href="/z/d/html/4845.html" rel="external">
          "Screening for melanoma in adults and adolescents", section on 'Performing skin examination'
         </a>
         ) and clinical evaluation of regional lymph nodes, every four to six months for the first two years, then annually. Follow-up can be managed by the patient's dermatologist and primary care physician; survivorship clinics are also an option. Patients should also be educated on the potential symptoms of disease recurrence. (See
         <a class="local">
          'Symptoms of recurrence or metastatic disease'
         </a>
         above.)
        </p>
        <p>
         UpToDate contributors diverge on the use of routine laboratory and imaging tests. Some contributors do not offer routine laboratory testing or imaging studies as part of surveillance because recurrences are less common in this population [
         <a href="#rid49">
          49
         </a>
         ]. Most retrospective series also demonstrate that the majority of recurrences (80 to 90 percent) are discovered by history and physical examination and not by imaging or laboratory studies [
         <a href="#rid45">
          45,50-53
         </a>
         ].
        </p>
        <p>
         However, other contributors obtain a complete blood count (CBC), serum lactate dehydrogenase (LDH) [
         <a href="#rid44">
          44
         </a>
         ], chest radiograph, and/or abdominal ultrasound (US) at each visit. While such studies may detect metastatic disease early, the overall yield is low. Routine blood tests (such as CBC, liver function tests, serum LDH), chest radiographs, and other imaging studies detect distant metastases in less than 10 percent of patients with early-stage disease [
         <a href="#rid51">
          51,54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3162945501">
         <span class="h2">
          Pathological stage IIB and IIIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with stage IIB or IIIA disease  (
         <a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/z/d/graphic/110663.html" rel="external">
          table 1A-B
         </a>
         ) who are receiving adjuvant therapy should initiate surveillance at the time they start treatment. Otherwise, we use a similar surveillance strategy for patients receiving adjuvant therapy and those on surveillance alone. (See
         <a class="medical medical_review" href="/z/d/html/7615.html" rel="external">
          "Adjuvant and neoadjuvant therapy for cutaneous melanoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A physical exam, including a total-body skin examination (see
         <a class="medical medical_review" href="/z/d/html/4845.html" rel="external">
          "Screening for melanoma in adults and adolescents", section on 'Performing skin examination'
         </a>
         ) and clinical evaluation of regional lymph nodes, every three to four months for the first two to three years, then every six months for up to five years. After five years, patients can continue with a physical exam annually with their dermatologist and primary care physician (with or without an oncologist) for surveillance of second or subsequent primary melanoma. (See
         <a class="medical medical_review" href="/z/d/html/4845.html" rel="external">
          "Screening for melanoma in adults and adolescents", section on 'Performing skin examination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CT of the chest, abdomen, and pelvis (and neck for those with primary tumors or lymph nodes involvement of the head and neck region) every six months for up to three years, then annually for up to five years. After five years, asymptomatic patients may be offered the option to discontinue imaging surveillance, after an informed discussion about the potential risks of recurrence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regional nodal US for those with a positive sentinel lymph node biopsy (SLNB) who did not undergo completion lymph node dissection (CLND). (See
         <a class="local">
          'Indications for nodal ultrasound during surveillance'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We do not obtain CNS imaging unless neurologic symptoms are present or extracranial metastatic disease is identified on other imaging studies.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3080232921">
         <span class="h2">
          Pathological stage IIC, IIIB, IIIC, IIID
         </span>
        </p>
        <p class="headingAnchor" id="H618349779">
         <span class="h3">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with stage IIC, IIIB, IIIC, and IIID disease are at higher risk for developing locoregional or metastatic disease [
         <a href="#rid52">
          52,55-57
         </a>
         ]. Therefore, surveillance of these patients typically involves more frequent follow-up and imaging studies than those with less-advanced disease. Patients who are receiving adjuvant therapy should initiate surveillance at the start of treatment. Our approach is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A physical exam, including a total-body skin examination (see
         <a class="medical medical_review" href="/z/d/html/4845.html" rel="external">
          "Screening for melanoma in adults and adolescents", section on 'Performing skin examination'
         </a>
         ) and clinical evaluation of regional lymph nodes, and CT of the chest, abdomen, and pelvis (and neck for those with primary tumors or lymph node involvement of the head and neck region) every three months for up the first three years, then every six months for up to five years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         After five years, patients can continue with a physical exam annually with their dermatologist and primary care physician (with or without an oncologist) for surveillance of second or subsequent primary melanoma. Additionally, asymptomatic patients may be offered the option to discontinue imaging surveillance, after an informed discussion about the potential risk of recurrence, which is estimated to be 5 percent or less [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CNS imaging is typically not indicated except for patients with neurologic symptoms or extracranial systemic disease recurrence. As an example, one observational study demonstrated limited utility for surveillance using MRI of the brain among patients with asymptomatic and continuously disease-free stage IIB-IIIC melanoma [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regional nodal US for those with a positive SLNB who did not undergo CLND. (See
         <a class="local">
          'Indications for nodal ultrasound during surveillance'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Regular surveillance with CT has consistent sensitivity and specificity over five years of follow-up in the contemporary era of systemic therapy for melanoma. As an example, in one retrospective study, 332 patients with stage IIIA to IIID melanoma received imaging surveillance with either CT or positron emission tomography (PET)-CT on a structured 6- and 12-month follow-up schedule [
         <a href="#rid60">
          60
         </a>
         ]. Using this schedule, CT imaging had a consistent sensitivity and specificity of 79 and 88 percent, respectively.
        </p>
        <p class="headingAnchor" id="H149799916">
         <span class="h3">
          Patients with in-transit/satellite metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with in-transit/satellite metastases, surveillance is similar to those with pathological stage IIC, IIIB, IIIC, and IIID disease. (See
         <a class="local">
          'Pathological stage IIC, IIIB, IIIC, IIID'
         </a>
         above.)
        </p>
        <p>
         One alternative approach is to obtain a whole-body fluorodeoxyglucose (FDG) PET-CT twice a year, in lieu of the surveillance CT scan planned for that time, to assess more broadly for soft tissue metastases in the trunk and extremities [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="local">
          'Indications for PET-CT during surveillance'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H204299449">
         <span class="h2">
          Distant metastatic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surveillance and early disease detection may be of consequence in the contemporary era of therapy for distant metastatic melanoma  (
         <a class="graphic graphic_algorithm graphicRef105384" href="/z/d/graphic/105384.html" rel="external">
          algorithm 1
         </a>
         ), where some patients can achieve complete responses and durable treatment-free survival. Our approach to surveillance in patients with metastatic disease is mainly based upon their treatment response. (See
         <a class="medical medical_review" href="/z/d/html/15863.html" rel="external">
          "Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Assessing treatment response'
         </a>
         .)
        </p>
        <p>
         In an observational study (PHAMOUS) of 1013 patients with distant metastasis diagnosed and treated in either Australia or the United States, median overall survival (OS) was higher for patients in the United States than Australia (16 versus 10 months) [
         <a href="#rid44">
          44
         </a>
         ]. This OS benefit was related to a six-month lead time in the detection of such metastases and was largely attributable to more aggressive surveillance in the United States, including more frequent visits and imaging surveillance.
        </p>
        <p class="headingAnchor" id="H2253853561">
         <span class="h3">
          Patients with stable disease or partial responses to therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surveillance is individualized for patients with metastatic disease with stable or partial responses to initial systemic therapy  (
         <a class="graphic graphic_algorithm graphicRef105384" href="/z/d/graphic/105384.html" rel="external">
          algorithm 1
         </a>
         ). Our general approach is to obtain a physical exam and cross-sectional imaging every three months. Options for imaging include CT of the chest, abdomen, and pelvis (and neck for those with primary tumors or lymph node involvement of the head and neck region) or whole-body PET-CT. The choice between these options is based upon the location of the tumors, timing of therapy, scan availability, and clinician preference.
        </p>
        <p>
         For patients on immunotherapy, some UpToDate contributors prefer CT scans to precisely measure tumor lesions and their response to therapy, especially during the first 12 weeks of therapy. PET-CT can be misleading during this early treatment period due to possible therapy-related immune responses. A whole-body PET-CT can be obtained at least once, ideally twelve months after initiating therapy, to identify a complete metabolic response to therapy (eg, residual tumor lesions on CT scans that are no longer FDG-avid) [
         <a href="#rid61">
          61
         </a>
         ] and to more broadly assess the trunk and extremities for evidence of disease. (See
         <a class="medical medical_review" href="/z/d/html/15863.html" rel="external">
          "Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Imaging studies'
         </a>
         .)
        </p>
        <p>
         Patients with extracranial distant metastatic disease only should be monitored for the development of CNS metastases. In these patients, we obtain magnetic resonance imaging (MRI) of the brain every six months for up to three years from the start of systemic therapy, then annually up to five years. After five years, patients may opt to discontinue CNS imaging after informed discussion of the risk of recurrence. MRI should also be obtained for restaging in patients who develop extracranial metastatic disease progression. Surveillance for those receiving therapy directed at CNS metastases is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7611.html" rel="external">
          "Management of brain metastases in melanoma", section on 'Surveillance and recurrent disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2528447524">
         <span class="h3">
          Patients with complete response to therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients treated with checkpoint inhibitor immunotherapy have the opportunity for treatment-free survival. (See
         <a class="medical medical_review" href="/z/d/html/15863.html" rel="external">
          "Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Treatment-free survival'
         </a>
         .)
        </p>
        <p>
         For patients with metastatic disease who achieve a complete response to therapy and have discontinued treatment, our general surveillance approach is to repeat CT of the chest, abdomen, and pelvis (and neck as indicated) every three months and MRI of the brain every six months for the first two years, then every six months for the third year, and then annually for years four and five. After year five, patients may discontinue imaging surveillance after an informed discussion on recurrence risk.
        </p>
        <p class="headingAnchor" id="H1988589158">
         <span class="h2">
          Special considerations
         </span>
        </p>
        <p class="headingAnchor" id="H3162572530">
         <span class="h3">
          Indications for PET-CT during surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Indications for obtaining a PET-CT during surveillance include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In-transit/satellite disease, particularly when the primary melanoma is located on an extremity. (See
         <a class="local">
          'Patients with in-transit/satellite metastases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To assess for a complete metabolic response to therapy. (See
         <a class="medical medical_review" href="/z/d/html/15863.html" rel="external">
          "Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Imaging studies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To evaluate lesions that are equivocal on CT for evidence of FDG-uptake more consistent with disease recurrence and require further imaging follow-up.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To rule out additional systemic metastases in patients who are contemplating surgery for isolated or oligometastatic disease.
        </p>
        <p>
        </p>
        <p>
         When used as part of surveillance, we prefer a full diagnostic CT scan as part of the PET-CT study, including contrast administration. Further technical details on this approach are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7625.html" rel="external">
          "Imaging studies in melanoma", section on 'FDG PET and PET/CT'
         </a>
         .)
        </p>
        <p>
         PET-CT or PET-MRI may be used outside the United States as part of surveillance [
         <a href="#rid62">
          62
         </a>
         ], but there are limited data supporting its routine use. Further data on the use of PET-MRI for imaging melanoma are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7625.html" rel="external">
          "Imaging studies in melanoma", section on 'MRI and PET/MRI'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7625.html" rel="external">
          "Imaging studies in melanoma", section on 'Brain'
         </a>
         .)
        </p>
        <p>
         Several systematic reviews suggest that surveillance PET-CT has reasonable accuracy to detect metastatic disease, with sensitivity ranging from 85 to 96 percent and specificity ranging from 79 to 95 percent [
         <a href="#rid1">
          1,63
         </a>
         ]. However, patients should be informed that an OS advantage with surveillance PET-CT imaging has not been established, and that the false-positive rate related to the stage of the disease can be relatively high (ranging from 10 to 15 percent) [
         <a href="#rid17">
          17,32,64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1323002790">
         <span class="h3">
          Indications for nodal ultrasound during surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         For any patients with a positive SLNB who do not undergo a CLND, we obtain regional lymph node US every four months during the first two years, and every six months for up to five years. Alternatively, patients on surveillance who are being evaluated every three months may be offered nodal US at every other visit. Nodal US surveillance may be discontinued after five years after an informed discussion with the patient about the potential risks of recurrence.
        </p>
        <p>
         This approach is preferred over CLND and is based on the active surveillance protocol used for patients in the observation arm of the Multicenter Selective Lymphadenectomy (MSLT) and DeCOG-SLT trials, which are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7616.html" rel="external">
          "Evaluation and management of regional nodes in primary cutaneous melanoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4157929221">
         <span class="h1">
          GENETIC TESTING
         </span>
         <span class="headingEndMark">
          —
         </span>
         During staging work-up and surveillance, patients may be identified who are at risk for hereditary melanoma syndromes. The indications to refer such patients for genetic testing are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7624.html" rel="external">
          "Inherited susceptibility to melanoma", section on 'Genetic testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H311844058">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118501.html" rel="external">
          "Society guideline links: Melanoma screening, prevention, diagnosis, and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2818052">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/889.html" rel="external">
          "Patient education: Melanoma treatment; localized melanoma (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/892.html" rel="external">
          "Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Staging work-up
         </strong>
         – Variability exists for the staging work-up of patients with cutaneous melanoma. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For those with a confirmed pathological diagnosis of primary melanoma  (
         <a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/z/d/graphic/110663.html" rel="external">
          table 1A-B
         </a>
         ), our approach is as follows (see
         <a class="local">
          'Staging work-up'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinically negative lymph nodes at presentation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Melanoma in situ and clinical/pathological stage IA
         </strong>
         – For asymptomatic patients, there is no established role for routine laboratory or imaging studies. (See
         <a class="local">
          'Melanoma in situ and clinical or pathological stage IA'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Clinical stage IIC (pT4 cN0)
         </strong>
         – CT of the chest, abdomen, and pelvis (CAP) and neck (the latter for primary tumors or regional nodes involving the head and neck region) prior to wide excision and sentinel lymph node biopsy (SLNB), if possible. (See
         <a class="local">
          'Clinical stage IIC (pT4b cN0)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinically evident nodal disease or in-transit/satellite metastases
         </strong>
         – For patients with an extremity primary, whole-body positron emission tomography (PET)-CT and magnetic resonance imaging (MRI) of the brain prior to further regional nodal evaluation, if possible. CT of the neck, chest, abdomen, and pelvis is an option for those with primary tumors of the head, neck, and trunk. (See
         <a class="local">
          'Clinically evident lymph nodes or in-transit/satellite metastases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Following pathological lymph node assessment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Pathological stage IB and IIA
         </strong>
         – For asymptomatic patients, most UpToDate contributors do not obtain routine imaging studies. (See
         <a class="local">
          'Pathological stage IB and IIA'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Pathological stage IIB and IIIA; IIC and IIIB
         </strong>
         – CT of the CAP (and neck, if indicated). For stage IIC and IIIB, whole-body PET-CT is an option for baseline imaging. (See
         <a class="local">
          'Pathological stage IIB and IIIA'
         </a>
         above and
         <a class="local">
          'Pathological stage IIC and IIIB'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         We do not generally obtain central nervous system (CNS) imaging unless patients have neurologic symptoms, extracranial metastatic disease, or are on clinical trials.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Pathological stage IIIC and IIID
         </strong>
         – Options include CT of the CAP (and neck, if indicated) or whole-body PET-CT, based on clinician preference and choice of adjuvant therapy. We obtain MRI of the brain in all patients. (See
         <a class="local">
          'Pathological stage IIIC and IIID'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Symptomatic disease or
         </strong>
         <strong>
          suspected metastases
         </strong>
         – Patients should be assessed prior to regional nodal evaluation, if possible, with CT of the CAP (and neck, as indicated) or whole-body PET-CT, serum lactate dehydrogenase (LDH), and MRI of the brain. (See
         <a class="local">
          'Symptomatic disease or suspected metastases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surveillance
         </strong>
         – Variability also exists for the surveillance of patients who are treated (or actively receiving systemic therapy), and our approach is as follows (see
         <a class="local">
          'Surveillance'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Total-body skin examination for all patients
         </strong>
         – For all patients, physical exam includes a total-body skin examination and clinical evaluation of regional lymph nodes. (See
         <a class="medical medical_review" href="/z/d/html/4845.html" rel="external">
          "Screening for melanoma in adults and adolescents", section on 'Performing skin examination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pathological stage IA
         </strong>
         – For most asymptomatic patients, physical exam every six months for the first two years, then annually. No routine laboratory or imaging tests are indicated. (See
         <a class="local">
          'Pathological stage IA'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pathological stage IB and IIA
         </strong>
         – For asymptomatic patients, physical exam every four to six months for the first two years, then annually. UpToDate contributors diverge on the use of routine laboratory or imaging tests. (See
         <a class="local">
          'Pathological stage IB and IIA'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pathological stage IIB and IIIA
         </strong>
         – For those on adjuvant therapy, surveillance should be initiated at the start of treatment. Otherwise, we use a similar strategy for those on adjuvant therapy and those on surveillance alone (see
         <a class="local">
          'Pathological stage IIB and IIIA'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Physical exam every three to four months for the first two to three years, then every six months for up to five years, then annually.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CT of the CAP (and neck, if indicated) every six months for up to three years, then annually for up to five years. After five years, asymptomatic patients may be offered the option to discontinue imaging surveillance after risk-benefit discussion.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Regional nodal ultrasound (US) as indicated. (See
         <a class="local">
          'Indications for nodal ultrasound during surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We do not obtain CNS imaging unless neurologic symptoms or extracranial metastatic disease is present.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pathological stage IIC, IIIB, IIIC, IIID
         </strong>
         – For those on adjuvant therapy, surveillance should be initiated at the start of treatment, which includes (see
         <a class="local">
          'Pathological stage IIC, IIIB, IIIC, IIID'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Physical exam and CT of the CAP (and neck, if indicated) every three months for up to the first three years, then every six months for up to five years. After five years, physical exam can be continued annually, and asymptomatic patients may be offered the option to discontinue imaging surveillance after risk-benefit discussion.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For those with in-transit/satellite metastases, PET-CT may be offered twice a year, in lieu of the surveillance CT scan planned for that time. (See
         <a class="local">
          'Patients with in-transit/satellite metastases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CNS imaging is typically not indicated except for neurologic symptoms or extracranial systemic disease recurrence.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Regional nodal US as indicated. (See
         <a class="local">
          'Indications for nodal ultrasound during surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Distant
         </strong>
         <strong>
          metastatic disease
         </strong>
         – Surveillance is individualized and based upon response to therapy. (See
         <a class="local">
          'Distant metastatic disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H129747181">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Merrick Ross, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Dinnes J, Ferrante di Ruffano L, Takwoingi Y, et al. Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. Cochrane Database Syst Rev 2019; 7:CD012806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morton RL, Craig JC, Thompson JF. The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol 2009; 16:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eguchi MM, Elder DE, Barnhill RL, et al. Prognostic modeling of cutaneous melanoma stage I patients using cancer registry data identifies subsets with very-low melanoma mortality. Cancer 2023; 129:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terhune MH, Swanson N, Johnson TM. Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol 1998; 134:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buzaid AC, Sandler AB, Mani S, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993; 11:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zartman GM, Thomas MR, Robinson WA. Metastatic disease in patients with newly diagnosed malignant melanoma. J Surg Oncol 1987; 35:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ardizzoni A, Grimaldi A, Repetto L, et al. Stage I-II melanoma: the value of metastatic work-up. Oncology 1987; 44:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khansur T, Sanders J, Das SK. Evaluation of staging workup in malignant melanoma. Arch Surg 1989; 124:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iscoe N, Kersey P, Gapski J, et al. Predictive value of staging investigations in patients with clinical stage I malignant melanoma. Plast Reconstr Surg 1987; 80:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassères N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 1995; 191:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bastiaannet E, Oyen WJ, Meijer S, et al. Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg 2006; 93:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005; 104:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fink AM, Holle-Robatsch S, Herzog N, et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res 2004; 14:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arrangoiz R, Papavasiliou P, Stransky CA, et al. Preoperative FDG-PET/CT Is an Important Tool in the Management of Patients with Thick (T4) Melanoma. Dermatol Res Pract 2012; 2012:614349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005; 46:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nijhuis AAG, Dieng M, Khanna N, et al. False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma. Ann Surg Oncol 2019; 26:1860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garbe C, Keim U, Amaral T, et al. Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol 2022; 40:3741.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Cutaneous melanoma. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf (Accessed on August 23, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi EA, Gershenwald JE. Imaging studies in patients with melanoma. Surg Oncol Clin N Am 2007; 16:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bronstein Y, Ng CS, Rohren E, et al. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. AJR Am J Roentgenol 2012; 198:902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996; 6:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gao G, Gong B, Shen W. Meta-analysis of the additional value of integrated 18FDG PET-CT for tumor distant metastasis staging: comparison with 18FDG PET alone and CT alone. Surg Oncol 2013; 22:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez Rivera AM, Alabbas H, Ramjaun A, Meguerditchian AN. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. Surg Oncol 2014; 23:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershenwald JE, Ross MI. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med 2011; 364:1738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orfaniotis G, Mennie JC, Fairbairn N, Butterworth M. Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland. J Plast Reconstr Aesthet Surg 2012; 65:1216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miranda EP, Gertner M, Wall J, et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 2004; 139:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janz TA, Neskey DM, Nguyen SA, Lentsch EJ. Is imaging of the brain necessary at diagnosis for cutaneous head and neck melanomas? Am J Otolaryngol 2018; 39:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Derks SHAE, de Joode K, Mulder EEAP, et al. The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma. ESMO Open 2022; 7:100600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold JS, Jaques DP, Busam KJ, et al. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. Ann Surg Oncol 2007; 14:2133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravichandran S, Nath N, Jones DC, et al. The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma. Surg Oncol 2020; 35:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koskivuo I, Kemppainen J, Giordano S, et al. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma. Acta Oncol 2016; 55:1355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stahlie EHA, van der Hiel B, Bruining A, et al. The value of lymph node ultrasound and whole body 18F-FDG PET/CT in stage IIB/C melanoma patients prior to SLNB. Eur J Surg Oncol 2021; 47:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dellestable P, Granel-Brocard F, Rat AC, et al. [Impact of whole body magnetic resonance imaging (MRI) in the management of melanoma patients, in comparison with positron emission tomography/computed tomography (TEP/CT) and CT]. Ann Dermatol Venereol 2011; 138:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaeger ZJ, Williams GA, Chen L, et al. 18 F-FDG positron emission tomography-computed tomography has a low positive predictive value for detecting occult recurrence in asymptomatic patients with high-risk Stages IIB, IIC, and IIIA melanoma. J Surg Oncol 2022; 125:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van de Wiele C, Juanito G, Vander BK, et al. Practical Considerations When Interpreting FDG PET/CT Imaging for Staging and Treatment Response Assessment in Melanoma Patients. Semin Nucl Med 2021; 51:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dietlein M, Krug B, Groth W, et al. Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis. Nucl Med Commun 1999; 20:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holder WD Jr, White RL Jr, Zuger JH, et al. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998; 227:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinert HC, Huch Böni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 195:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinhardt MJ, Joe AY, Jaeger U, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006; 24:1178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005; 6:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francken AB, Accortt NA, Shaw HM, et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg 2008; 95:1401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trotter SC, Sroa N, Winkelmann RR, et al. A Global Review of Melanoma Follow-up Guidelines. J Clin Aesthet Dermatol 2013; 6:18.
          </a>
         </li>
         <li class="breakAll">
          Atkins MB, Long GV, Warneke CL, et al Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study. J Clin Oncol 28:15s, 2010 (suppl; abstr 8516)
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francken AB, Shaw HM, Accortt NA, et al. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 2007; 14:1924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003; 97:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiFronzo LA, Wanek LA, Elashoff R, Morton DL. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol 1999; 6:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 2017; 376:2211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg 1995; 221:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995; 274:1703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garbe C, Paul A, Kohler-Späth H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003; 21:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol 2009; 16:941.
          </a>
         </li>
         <li class="breakAll">
          Cutaneous Melanoma: Etiology and Therapy, Codon Publications.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Podlipnik S, Carrera C, Sánchez M, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. J Am Acad Dermatol 2016; 75:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 2010; 28:3042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johannet P, Simons M, Qian Y, et al. Risk and tropism of central nervous system (CNS) metastases in patients with stage II and III cutaneous melanoma. Cancer 2022; 128:3620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeRose ER, Pleet A, Wang W, et al. Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma. Melanoma Res 2011; 21:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner RM, Dieng M, Khanna N, et al. Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA-D Melanoma. Ann Surg Oncol 2021; 28:4561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibney GT, Zaemes J, Shand S, et al. PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma. J Immunother Cancer 2021; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dummer R, Siano M, Hunger RE, et al. The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly 2016; 146:w14279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danielsen M, Højgaard L, Kjær A, Fischer BM. Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. Am J Nucl Med Mol Imaging 2013; 4:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vensby PH, Schmidt G, Kjær A, Fischer BM. The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis. Am J Nucl Med Mol Imaging 2017; 7:255.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7621 Version 40.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31260100" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19030934" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29028110" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36336975" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prognostic modeling of cutaneous melanoma stage I patients using cancer registry data identifies subsets with very-low melanoma mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9606326" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Use of chest radiography in the initial evaluation of patients with localized melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8478659" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Role of computed tomography in the staging of primary melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3599990" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Metastatic disease in patients with newly diagnosed malignant melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3574855" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Stage I-II melanoma: the value of metastatic work-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2742488" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Evaluation of staging workup in malignant melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3602173" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Predictive value of staging investigations in patients with clinical stage I malignant melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8534937" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16323165" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15977211" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15057045" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22654898" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Preoperative FDG-PET/CT Is an Important Tool in the Management of Patients with Thick (T4) Melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15872346" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Detection of unexpected additional primary malignancies with PET/CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30911946" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35709414" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35709414" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17560520" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Imaging studies in patients with melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22451559" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8873053" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Positron emission tomography in the detection and management of metastatic melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23886614" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Meta-analysis of the additional value of integrated 18FDG PET-CT for tumor distant metastasis staging: comparison with 18FDG PET alone and CT alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24556310" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21542744" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Sentinel-lymph-node biopsy for cutaneous melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22525255" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15302691" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29929862" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Is imaging of the brain necessary at diagnosis for cutaneous head and neck melanomas?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36265261" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17453294" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33161362" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27553064" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33353826" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The value of lymph node ultrasound and whole body 18F-FDG PET/CT in stage IIB/C melanoma patients prior to SLNB.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21570561" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : [Impact of whole body magnetic resonance imaging (MRI) in the management of melanoma patients, in comparison with positron emission tomography/computed tomography (TEP/CT) and CT].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34741547" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : 18 F-FDG positron emission tomography-computed tomography has a low positive predictive value for detecting occult recurrence in asymptomatic patients with high-risk Stages IIB, IIC, and IIIA melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34246450" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Practical Considerations When Interpreting FDG PET/CT Imaging for Staging and Treatment Response Assessment in Melanoma Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10093075" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9605668" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Effectiveness of positron emission tomography for the detection of melanoma metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7753998" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16505438" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16054572" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Follow-up in patients with localised primary cutaneous melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18844268" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Follow-up schedules after treatment for malignant melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24062870" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A Global Review of Melanoma Follow-up Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24062870" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A Global Review of Melanoma Follow-up Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17357855" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15342808" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Management of cutaneous melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12548605" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10560858" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28591523" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7748038" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Melanoma recurrence surveillance. Patient or physician based?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7474276" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12560444" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19101766" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19101766" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27183845" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20479405" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36006879" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Risk and tropism of central nervous system (CNS) metastases in patients with stage II and III cutaneous melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8558223" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21540750" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33393039" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA-D Melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34599027" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26901103" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24380042" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29348980" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
